Maplight Therapeutics (NASDAQ:MPLT - Get Free Report)'s stock had its "buy" rating restated by Canaccord Genuity Group in a research report issued on Tuesday, Benzinga reports. They currently have a $21.00 target price on the stock. Canaccord Genuity Group's price target suggests a potential upside of 214.84% from the stock's previous close.
MPLT has been the topic of a number of other research reports. Wall Street Zen downgraded Maplight Therapeutics from a "sell" rating to a "strong sell" rating in a research note on Sunday, November 8th. Jefferies Financial Group reaffirmed a "buy" rating on shares of Maplight Therapeutics in a report on Monday, July 27th. Wolfe Research reiterated an "outperform" rating and set a $30.00 price target on shares of Maplight Therapeutics in a research report on Monday, July 27th. Raymond James Financial set a $31.00 price target on Maplight Therapeutics in a report on Friday, August 14th. Finally, BMO Capital Markets initiated coverage on Maplight Therapeutics in a research report on Monday, July 20th. They set an "outperform" rating and a $46.00 price objective for the company. Four equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $29.50.
View Our Latest Stock Analysis on MPLT
Maplight Therapeutics Stock Down 3.3%
Shares of NASDAQ:MPLT traded down $0.23 on Tuesday, reaching $6.67. 46,014 shares of the company's stock were exchanged, compared to its average volume of 458,619. The business's 50-day moving average is $9.20 and its two-hundred day moving average is $19.79. Maplight Therapeutics has a fifty-two week low of $6.06 and a fifty-two week high of $40.43. The firm has a market capitalization of $370.72 million and a price-to-earnings ratio of -0.16.
Maplight Therapeutics (NASDAQ:MPLT - Get Free Report) last posted its quarterly earnings results on Monday, November 16th. The company reported ($0.97) EPS for the quarter, beating the consensus estimate of ($1.22) by $0.25. Analysts predict that Maplight Therapeutics will post -5.01 earnings per share for the current fiscal year.
Insider Buying and Selling at Maplight Therapeutics
In related news, insider Anatol Kreitzer sold 12,248 shares of the firm's stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $7.84, for a total value of $96,024.32. Following the sale, the insider directly owned 168,678 shares in the company, valued at $1,322,435.52. This trade represents a 6.77% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Erin Pennock Foff sold 15,355 shares of the firm's stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $8.08, for a total value of $124,068.40. Following the completion of the sale, the insider owned 296,906 shares in the company, valued at approximately $2,399,000.48. This represents a 4.92% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 122,974 shares of company stock valued at $990,690. 3.80% of the stock is currently owned by insiders.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently modified their holdings of the business. Global Retirement Partners LLC increased its holdings in shares of Maplight Therapeutics by 5,244.4% during the third quarter. Global Retirement Partners LLC now owns 3,367 shares of the company's stock valued at $34,000 after purchasing an additional 3,304 shares during the period. Legal & General Group Plc bought a new stake in shares of Maplight Therapeutics during the second quarter valued at about $37,000. The Manufacturers Life Insurance Company bought a new stake in shares of Maplight Therapeutics during the second quarter valued at about $252,000. Deutsche Bank AG acquired a new stake in Maplight Therapeutics in the second quarter worth about $370,000. Finally, Jump Financial LLC lifted its holdings in Maplight Therapeutics by 131.8% in the third quarter. Jump Financial LLC now owns 58,461 shares of the company's stock worth $596,000 after purchasing an additional 33,239 shares during the period.
About Maplight Therapeutics
(
Get Free Report)
MapLight Therapeutics is a clinical-stage biopharmaceutical company developing medicines for people with serious brain disorders. Its research focuses on treatments intended to address symptoms that can be difficult to manage with existing therapies. The company's investigational programs include ML-007 for schizophrenia and ML-004 for autism spectrum disorder. These candidates remain in development and are not approved medicines.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Maplight Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maplight Therapeutics wasn't on the list.
While Maplight Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.